Jeffrey Goldberg, MD, PhD

Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Glaucoma cure may be found in newly discovered biomarkersThe study of biomarkers for glaucoma is pointing to promising avenues for new treatments, according to Vivek J. Srinivasan, PhD.
Therapeutic advances in glaucoma focus on retinal ganglion cell pathologyFindings from basic science research elucidating the mechanisms of retinal ganglion cell axon degeneration, regeneration, and death have identified new therapeutic targets for glaucoma that are being investigated in preclinical and clinical studies.
Biomarker research centers on early glaucoma diagnosisThe search for glaucoma biomarkers is in high gear. Funded by Catalyst for a Cure, the research program has already produced new biomarker candidates and novel techniques that promise to advance research in glaucoma. Research is focusing on ways to diagnose glaucoma early and detect the specific, minute changes that could allow researchers to reduce vision loss.
Catalyst for a Cure team establishes targets for glaucoma biomarkersSeveral years ago, the Glaucoma Research Foundation (GRF) expanded its initiative to advance glaucoma research through a collaborative approach by creating a second Catalyst for a Cure research team.